SBIR TOPIC 081: ADJUVANT DEVELOPMENT FOR VACCINES AGAINST INFECTIOUS OR IMMUNE-MEDIATED DISEASES

Antagen Pharmaceuticals, Inc., Boston MA

Investigators

Abstract

This contract is part of the NIAID Adjuvant Development program, which supports the preclinical development of novel vaccine adjuvant candidates. The goal of this contract is to support the further development of the C3d-CTB adjuvant within the context of a vaccine to protect against H. pylori.